Perform liver function tests prior to initiation of treatment & periodically thereafter. Haemorrhagic stroke or lacunar infarct. Measure creatine phosphokinase (CPK) prior to treatment in patients w/ renal impairment, hypothyroidism; history of hereditary muscular disorders, muscular toxicity w/ statins or fibrates, liver disease &/or substantial alcohol consumption, elderly >70 yr. Discontinue use if significant CPK elevation (>5 times ULN) or if muscular symptoms are severe even if the CPK levels are elevated to ≤5 times ULN, or if clinically significant elevation of CPK levels (>10 times ULN) occurs or if rhabdomyolysis is diagnosed or suspected. Temporarily w/hold or discontinue treatment in patients w/ acute, serious condition suggestive of a myopathy or w/ risk factor predisposing to renal failure secondary to rhabdomyolysis (eg, severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine & electrolyte disorders, & uncontrolled seizures). Concomitant use w/ ciclosporin, erythromycin, clarithromycin, itraconazole, ketoconazole, nefazodone, niacin, gemfibrozil, other fibric acid derivatives or HIV-PIs; ezetimibe. Patients <18 yr (for treatment periods >52 wk). Childn <10 yr & premenarchal girls. Long-term effects on cognitive development, growth & pubertal maturation. Rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.